In Vitro Investigation of HIF-1α as a Therapeutic Target for Thyroid-Associated Ophthalmopathy.

Endocrinol Metab (Seoul) · 2024 · PMC11525702 · PMID 39410849

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significantP =0.06so close (0.05 < p ≤ 0.1)

Specifically, the expression of HIF-1α showed a borderline significant decrease ( P =0.06), CEBP expression demonstrated a significant reduction ( P =0.007), and PPARγ expression did not exhibit a significant change ( P =0.5530).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.